The EU's strategic rebalancing of research partnerships with China

Key Takeaways

In 2026, the EU's €93 billion Horizon Europe research program introduced significant changes to its international cooperation rules.
Chinese organizations are now largely ineligible for EU funding in critical technological areas, including artificial intelligence, semiconductors, quantum technologies, and biotechnology.
This policy shift is driven by heightened concerns over research security, intellectual property protection, and potential strategic technology transfers.
While cooperation continues in fields like climate science and agriculture, the move signals a fundamental recalibration of Europe's scientific engagement.
The rebalancing reflects a broader EU emphasis on strategic autonomy, aligning science policy with geopolitical realities and economic sovereignty.

What Happened

In 2026, Europe's ambitious €93 billion research and innovation framework, Horizon Europe, underwent a notable transformation. What was once a more open invitation for global researchers has adopted a more guarded stance. Specifically, in critical technology sectors such as artificial intelligence, semiconductors, quantum technologies, and biotechnology, organizations based in China are no longer automatically eligible to receive EU funding. This marks a significant departure from earlier years, when Chinese participation was possible, albeit under evolving conditions, often requiring them to join as Associated Partners and provide their own financing.

Late in 2025, the European Commission codified these conditions, effectively blocking Chinese institutions from securing core Horizon Europe grants in sensitive research clusters. The updated rules now necessitate that European partners demonstrate their collaborators are not owned or controlled by Chinese entities, creating de facto barriers for extensive bilateral work in cutting-edge fields.

Why It Matters

This change is more than a mere bureaucratic adjustment; it represents a fundamental shift in the EU's approach to global scientific collaboration. Over the past decade, China has become an increasingly prominent player in international scientific networks, with its researchers frequently co-authoring papers with European counterparts and its domestic science base growing rapidly. However, under the revised Horizon Europe architecture, participation by Chinese entities is no longer synonymous with access to EU funds.

This distinction profoundly alters the incentives and power dynamics within collaborative research. The new rules necessitate that European institutions carefully consider eligibility constraints when forming partnerships in emerging technologies, adding layers of administrative complexity and strategic planning. Furthermore, these restrictions carry the risk of unintended intellectual and scientific consequences, potentially leading to the evolution of parallel research ecosystems with reduced interoperability. Such a development could reshape global science into distinct blocs, impacting citation networks, collaborative norms, and researcher mobility.

Key Details / Context

The official justifications for these policy adjustments, as outlined by the European Commission, focus on critical issues of research security, the protection of intellectual property, and mitigating the perceived risk of unintended transfers of strategic technology, particularly where civil and military applications may overlap. While the EU maintains its commitment to open scientific cooperation, it acknowledges the deep intertwining of the research ecosystem with global power dynamics.

Despite the tightened restrictions within Horizon Europe, the EU has not entirely abandoned bilateral scientific engagement with China. Cooperation continues in non-sensitive areas such as climate science and agriculture, supported by existing bilateral road-map mechanisms. Additionally, mechanisms outside Horizon Europe, including various mobility schemes and targeted co-funding instruments designed to facilitate researcher exchanges, remain active. This nuanced approach highlights that science policy in Europe is increasingly positioned at the intersection of research excellence, economic sovereignty, and broader geopolitical strategy.